Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
95 results about "Infection drug" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Ciprofloxacin/dexamethasone (Ciprodex) is an expensive drug used to treat ear infections. It also stops the swelling and itching caused by the infection. This drug is more popular than comparable drugs.
Human CCR5 gene target sequence recognized by streptococcus thermophilus CRISPR (clustered regularly interspaced short palindromic repeat)-Cas9 (CRISPR-associated protein 9) system, sgRNA (single guide ribonucleic acid) and application
InactiveCN105331607AAchieve preventionAchieve therapeutic effectGenetic material ingredientsAntiviralsGene targetsA-DNA
Owner:张竞方
Recombinant gene construction of chimeric antigen receptor (CAR) for treating HIV (human immunodeficiency virus) infection and application of chimeric antigen receptor
ActiveCN107098969AHigh broad spectrumIncrease heightPeptide/protein ingredientsAntibody mimetics/scaffoldsSingle-Chain AntibodiesT lymphocyte
The invention relates to the technical field of immunotherapy of infectious diseases, in particular to recombinant gene construction of chimeric antigen receptor (CAR) for treating HIV (human immunodeficiency virus) infection and an application of the CAR. A single-chain antibody (ScFv) can identify gp120 of surfaces of HIV infected cells through series connection of antibody light chain and heavy chain variable zones of the gp120 of the surfaces of the HIV infected cells; the ScFv is prepared into the CAR, CAR coding genes are shifted to plasimid vectors, and lentiviral vectors shifted with the CAR coding genes are transduced to CD8+T lymphocytes. The CD8+T lymphocytes are discovered to be remarkable in restraining and killing activities of the HIV infected cells in both in-vitro and in-vivo experiments and can serve as active ingredients to prepare anti-HIV infection drugs, and good application prospect is achieved.
Owner:WUHAN BIO RAID BIOTECH CO LTD
Construction method of kidney transplantation anti-infection drug dosage prediction model
ActiveCN113035369ARapid MedicationAccurate MedicationMolecular designDrug referencesBlood drug concentrationPharmacology
The invention provides a construction method of a kidney transplantation anti-infection drug dosage prediction model. The method comprises the following steps: establishing a group pharmacokinetic model of an anti-infective drug by adopting a nonlinear mixed effect model, a two-atrioventricular model and a mixed residual model through plasma concentration analysis, and calculating pharmacokinetic parameters of the corresponding model; and carrying out related hypothesis testing and estimation on the obtained model pharmacokinetic parameters based on a bootstrap method, visual prediction testing and normalized prediction distribution errors, and completing the steps of stability and prediction capability evaluation and the like. According to the established pharmacokinetic model of the kidney transplantation patient population, the reasonable judgment on the medication scheme information is accurately realized, the reference of the optimal dosage is expected to be provided in the infection prevention and treatment process, the adverse reaction risk is reduced, the curative effect is improved, and finally the individualized administration of the anti-infection medicine of the kidney transplantation patient is realized.
Owner:ZHEJIANG UNIV
In-situ rapid detection method for cell biological process
ActiveCN107741417ARealize in-situ rapid detectionQuick judgmentRaman scatteringHuman bodyActive cell
The invention relates to an in-situ rapid detection method for a cell biological process. After absorption, conversion, metabolism or storage for deuterium-containing matters based on active cells, in-situ marking for deuterium in cells can be realized in different stages of the cell biological process, the cells are detected through a Raman spectrum, whether deuterium exists in the cells is identified, and then the biochemical process, cell character or function related information about the cells is obtained. The method can be used for biological and medical fields such as bacterial infection drug susceptibility testing, environmental microbial metabolism and human body cell detection. Compared with the prior art, the method has the potential of detecting the activity and metabolism of the cells for most important biomolecules, and more complex deuteration matters are allowed to be researched and used, including natural products, medicines and a deuterization mixture containing various chemical matters. The method is extremely valuable for function research of the cells under natural conditions of single cell level.
Owner:上海氘峰医疗科技有限公司
Polydopamine-coated Prussian blue and silver-loaded nano-composite material, and preparation method and application thereof
InactiveCN111001002AGood dispersionImprove antibacterial propertiesAntibacterial agentsEnergy modified materialsAntimicrobial drugPotassium ferricyanide
The invention discloses a polydopamine-coated Prussian blue and silver-loaded nano-composite material, and a preparation method and an application thereof. The composite material is formed by coatingPrussian blue with polydopamine and then growing nano-silver on the polydopamine in situ, and the particle size of the composite material is 100-150 nm. The preparation method comprises the followingsteps: reacting potassium ferricyanide with polyvinylpyrrolidone to obtain Prussian blue, adding dopamine into a Tris-HCl solution of Prussian blue to prepare polydopamine-coated Prussian blue, and mixing and stirring the obtained polydopamine-coated Prussian blue dispersion, ammonia water, a reducing agent and a silver nitrate solution to react in order to make nano-silver grows on the coating layer polydopamine in situ in order to obtain the product. The nano-composite material has a good antibacterial effect, is not prone to causing drug resistance of bacteria, has good stability and dispersity, the preparation method has the advantages is simple and mild, short in time consumption, low in energy consumption and easy to realize large-scale production, and the nano-composite material canbe used for preparing photo-thermal antibacterial drugs or chronic traumatic infection treatment drugs.
Owner:HUNAN UNIV
Application of p-hydroxybenzoic acid and its analogue in the preparing process of medicine for preventing and treating skin mucous membrane virus infection
The invention discloses an application of p-hydroxybenzoic acid and analogue in the skin virus infection drug, which is characterized by the following: fitting for infectious drug of people breast tumour virus and herpetoviridae virus; allocating each auxiliary material to prepare different agent or personal nursing product.
Owner:SHENGHUA GUANGZHOU PHARMA SCI & TECH
Use of Levo-Ornidazole For Preparing Anti-Parasitic Infection Drug
PendingUS20080177083A1Low toxicityImprove securityOrganic active ingredientsOrganic chemistryDrugs preparationsTrichomonas vaginalis
The use of levo-ornidazole in the preparation of anti-parasitic infection drug is provided. It is demonstrated that levo-ornidazole is superior to dextro-ornidazole and racemic ornidazole in the therapeutic action against parasitization (especially trichomonas vaginalis infection and cecal amoeba infection), and thus it is more practicable to formulate L-ornidazole as anti-parasitic infection drugs, and particularly as drug preparations which are suitable for clinical uses, including oral preparation, intravenous preparation and vaginal preparation.
Owner:NANJING SANHOME PHARMACEUTICAL CO LTD
Application of G protein coupling receptor 18 agonist in preparation of infection drugs
InactiveCN106344922AInhibit inflammationInhibitory reactivityAntibacterial agentsHydroxy compound active ingredientsImmunologic disordersDisease
The invention provides application of G protein coupling receptor 18 agonist in the preparation of infection drugs; an endotoxin-induced rat is treated with the G protein coupling receptor 18 agonist, lung tissues of the rat are taken on first, third, fifth and seventh days, pathogenic condition of tissue inflammation is observed, it can be seen from pictures that the G protein coupling receptor 18 agonist can significantly inhibit inflammation and immunity symptom reaction of the endotoxin-induced rat, and therefore, the G protein coupling receptor 18 agonist is applicable to the treatment of infection and immunity diseases; the G protein coupling receptor 18 agonist is significantly effective in inhibiting endotoxin-induced lung tissue inflammation reaction and is applicable to the preparation of drugs for treating sepsis infections; scientific evidences are provided for the clinical application of the G protein coupling receptor 18 agonist in treating sepsis infections.
Owner:安徽济人药业股份有限公司
Spina gleditsiae extract hydrogel patch and preparation method thereof
InactiveCN102309539ASave raw materialsSmall particlesDigestive systemImmunological disordersCelluloseGlycerol
The invention discloses a spina gleditsiae extract hydrogel patch and a preparation method thereof, and belongs to the technical field of pharmaceutic preparation. The spina gleditsiae extract hydrogel patch is formed by mixing a spina gleditsiae extract and a blank hydrogel substrate; the phenolic acid compound contend of the spina gleditsiae extract is 6-7 mg / ml; the blank hydrogel substrate is formed by stirring and mixing an oil phase and a water pahse, wherein the weight ratio of the oil phase and the water phase is 50-60:100; the components of the oil phase are glycerin, polyacrylic acid, dihydroxyaluminum aminoucetate, and azone; the components of the water phase are water, carboxymethylcellulose sodium, tartaric acid, EDTA-2Na, and titanium dioxide. The spina gleditsiae extract hydrogel patch of the invention has simple substrate prescription, high water content, and strong affinity, is reliable and stable, has no irritation to skin, has good anti-infection drug effect activity, allows convenient addition of various Chinese herbal medicine extracts, and is widely applicable to aspects such as surgical wounds, general wounds, skin infection, cosmetology and skin beautification, and the like.
Owner:GUANGDONG PHARMA UNIV
Application of oxidized resveratrol and combined oxidized resveratrol and antibiotic in preparation of anti-fungal-infection product
ActiveCN107213142AImprove securityNatural developmentAntimycoticsHydroxy compound active ingredientsCandida famataAntibiotic Y
The invention relates to application of oxidized resveratrol and combined oxidized resveratrol and antibiotic in the preparation of an anti-fungal-infection product, belonging to the technical field of medicines. Oxidized resveratrol contains nautical components, is good in safety and has good antibacterial capacity to trichophyton rubrum and Candida albicans. When the oxidized resveratrol and an antibiotic, namely econazole nitrate jointly act on the two bacteria, the antibacterial effects on the two bacteria are superior to the antibacterial effects of dependent independent oxidized resveratrol and antibiotic on the two bacteria under the same use concentration, so that natural oxidized resveratrol is used for replacing partial econazole nitrate so as to inhibit fungi, the use amount of econazole nitrate can be reduced, and the research and development of novel, efficient and natural anti-fungal-infection drugs are benefited.
Owner:SOUTHWEST UNIVERSITY
Composite biological patch as well as preparation method and application thereof
ActiveCN113663137AHelp slow releaseImprove adhesionPharmaceutical delivery mechanismTissue regenerationRepair tissueBreast repair
The invention provides a composite biological patch as well as a preparation method and an application thereof, and relates to the technical field of medical treatment. The composite biological patch provided by the invention comprises a hydrophobic porous layer, a compact layer and a porous scaffold, the hydrophobic porous layer is opposite to one side of a to-be-repaired tissue and is loaded with an anti-infection drug, the hydrophobicity of the hydrophobic porous layer and the loaded drug can be matched with each other, the drug can be slowly released, and the effects of prevention, anti-infection and anti-adhesion are achieved; the porous scaffold has a porous structure, faces one side of a to-be-repaired tissue, is beneficial to adhesion and growth of cells, and induces membrane tissue regeneration; the hydrophobic porous layer and the porous scaffold spacing compact layer can ensure the dimensional stability and mechanical strength of the product, and also can play a role of a barrier. The composite biological patch provided by the invention can be used for meninx repair, spinal meninx repair, rotator cuff repair, hernia repair, ophthalmology repair, breast repair, hemostasis repair or oral cavity repair.
Owner:BEIJING BONSCI TECH CO LTD
Preparation method and application of effective components of polygonum capitatum
ActiveCN103432214AImprove efficiencyImprove efficacyAntibacterial agentsAgainst vector-borne diseasesPolyamideChromatographic column
The invention relates to a preparation method and application of effective components of polygonum capitatum, and belongs to the field of extraction of effective components of traditional Chinese medicines. The preparation method comprises the following steps: a, taking polygonum capitatum medicinal raw material, adding water for extraction, so as to obtain water extracting solution; b, processing the water extracting solution by using a macroporous adsorption resin chromatographic column; c, firstly eluting the sampled macroporous adsorption resin chromatographic column by using water, then eluting by using 70-95wt% ethanol, and collecting eluent I; d, processing the eluent I by a polyamide chromatographic column; e, recovering effluent liquid from the sampled polyamide chromatographic column, eluting by using 40-95wt% ethanol, collecting eluent II; f, mixing the effluent liquid and the eluent II, recovering ethanol, concentrating and drying to finally obtain the effective components of polygonum capitatum. The preparation method has the beneficial effect that the effective components of the polygonum capitatum, which has strong antibacterial effect and can be used for preparing anti-infection drugs can be prepared by reasonable extracting and separating methods.
Owner:GUIYANG MEDICAL UNIVERSITY
Structure and application of anti-ev71, Japanese encephalitis and influenza virus oligonucleotide targeting csnk2a2
InactiveCN102296066AFree from diseaseStrong specificityGenetic material ingredientsAntiviralsEnterovirusDisease
The invention relates to the structure and application of an antisense oligonucleotide drug. Specifically, the structure of antisense oligonucleotides targeting casein kinase 2, alpha propeptide, and anti-enterovirus type 71, Japanese encephalitis virus and influenza virus was found, and these antisense oligonucleotides were found in Use in the preparation of medicines for treating EV71, Japanese encephalitis virus and influenza virus infection and related diseases.
Owner:INST OF RADIATION MEDICINE ACAD OF MILITARY MEDICAL SCI OF THE PLA
Use of Levo-Ornidazole in the Preparation of Anti-Anaerobic Bacteria Infection Drugs
ActiveUS20090326030A1Improve the balance effectSignificant effect coordinationAntibacterial agentsBiocideAnaerobic infectionOrnidazole
The use of levo-ornidazole in the preparation of medicine for preventing and treating the anti-anaerobic bacteria infection is provided. It is demonstrated that levo-ornidazole exhibits lower toxicity and less central inhibition effects than dextro-ornidazole or racemic ornidazole. L-ornidazole possesses pharmacokinetics characteristics, which are superior to that of the racemic ornidazole, and anti-anaerobic activities which are slightly better than or substantially the same as that of the racemic ornidazole. Also, this invention particularly relates to a preparation process, which comprises formulating L-ornidazole as anti-anaerobic infection pharmaceutical preparations, which are suitable for clinical uses.
Owner:NANJING SANHOME PHARMACEUTICAL CO LTD
Antibacterial peptide P104 and lyase LysP53 with broad-spectrum splitting activity, and application of antibacterial peptide P104 and lyase LysP53
ActiveCN113549610ABroad-spectrum crackingBroad-spectrum lytic activityAntibacterial agentsBacteriaLyaseBacilli
The invention discloses an antibacterial peptide P104 and lyase LysP53 with the broad-spectrum splitting activity, and application of the antibacterial peptide P104 and the lyase LysP53. The amino acid sequence of the antibacterial peptide P104 is as shown in SEQ ID NO.1, and the gene sequence of the antibacterial peptide P104 is as shown in SEQ ID NO.3; the amino acid sequence of the lyase LysP53 is as shown in SEQ ID NO.2, and the gene sequence of the lyase LysP53 is as shown in SEQ ID NO.4; the antibacterial peptide P104 and the lyase LysP53 have a relatively good splitting effect on acinetobacter baumannii, pseudomonas aeruginosa, klebsiella pneumoniae and escherichia coli in vitro, and can be used for splitting gram-negative bacteria in a broad-spectrum manner; meanwhile, the lyase LysP53 can be subjected to soluble expression in escherichia coli, and the enzyme activity is high, and thus, the antibacterial peptide P104 and the lyase LysP53 have relatively good application prospects in research and development of anti-infection drugs.
Owner:WUHAN INST OF VIROLOGY CHINESE ACADEMY OF SCI
Dryopteris fragrans phloroglucinol derivatives, separation and preparation method for isomers thereof and application thereof
ActiveCN105061179AGood medicinal activityHigh purityAntimycoticsDermatological disorderSide effectInfection drug
The present invention relates to the technical field of medicines and discloses dryopteris fragrans phloroglucinol derivatives, a separation and preparation method for isomers thereof and an application thereof Phloroglucinol compounds are separated and prepared from dryopteris fragrans(L.)Schott, which belongs to dryopteridaceae dryopteris plants, for the first time, and 4 pairs of isomers are discovered, wherein the 4 pairs of isomeric compounds have relatively strong effect of resisting skin superficial fungi. According to the in-vitro bacteriostatic experiment, the compounds provided by the present invention have good bacteriostatic effect on two skin pathogenic fungi, namely trichophyton rubrum and microsporum gypseum, and have characteristics of being low in side effect and being not liable to become resistant to the drug, and the like, thereby providing a novel natural compound for the treatment of skin superficial fungi infection and providing powerful technical support for preparing anti skin superficial fungi infection drugs or pharmaceutical compositions.
Owner:GUANGDONG PHARMA UNIV
Application of 2,6-bis(2-benzimidazolyl) pyridine in preparation of carbapenem-resistant pseudomonas aeruginosa infection drug
ActiveCN111658646AInhibition of active effluxLow inhibitory concentrationAntibacterial agentsOrganic active ingredientsMeropenemBisbenzimidazole
The invention discloses application of 2,6-bis(2-benzimidazolyl) pyridine in preparation of a carbapenem-resistant pseudomonas aeruginosa infection drug. Through circular dichroism, fluorescent real-time quantitative PCR and other methods, it is found that 2, 6-bis (2-benzimidazolyl) pyridine can form a G-quadruplex structure with a core sequence of a MexA gene in pseudomonas aeruginosa, thereby inhibiting expression of the MexA gene. A susceptibility testing verifies that 2, 6-bis (2-benzimidazolyl) pyridine can reduce the drug resistance of carbapenem-resistant pseudomonas aeruginosa to meropenem. When the usage amount of the 2, 6-bis (2-benzimidazolyl) pyridine is 5 <mu>M, the minimum inhibitory concentration of the carbapenem-resistant pseudomonas aeruginosa strain can be reduced to 2<mu> g / ml, and the effect of treating carbapenem-resistant pseudomonas aeruginosa infection by using meropenem is achieved.
Owner:HENAN UNIVERSITY OF TECHNOLOGY
Efficient antibacterial activity antisense nucleic acid sequence of multidrug resistant Acinetobacter baumannii
InactiveCN103571836AVerify the validity of the bindingAntibacterial agentsGenetic material ingredientsComputer Aided DesignAntisense nucleic acid
The present invention discloses an antisense oligonucleotide sequence for inhibiting growth of multidrug resistant Acinetobacter baumannii, and an application thereof, and belongs to the field of novel antibacterial preparation research and development. According to the invention, the computer-assisted design and oligonucleotide dot blot hybridization combined technology is adopted to screen the antisense oligonucleotide adopting coding gene gyrA of the multidrug resistant Acinetobacter baumannii topoismerase IIA subunit as target gene so as to inhibit growth of multidrug resistant Acinetobacter baumannii; the antisense oligonucleotide sequence has significant multidrug resistant Acinetobacter baumannii growth inhibition activity at a low concentration, and can present rapid and efficient bactericidal activity (ie., cause death of multidrug resistant Acinetobacter baumannii) when the concentration is increased; and the designed antisense nucleic acid has characteristics of strong inhibition activity and high specificity, is suitable for treatment of multidrug resistant Acinetobacter baumannii infections, and can be potentially developed into the anti-multidrug resistant Acinetobacter baumannii infection drug.
Owner:夏云 +2
Cq-Ns1abp gene for inhibiting WSSV infection and application of protein thereof in resistance of virus activity
ActiveCN108558993AStrong infectious activityInhibition of infection replicationPeptide/protein ingredientsAccessory food factorsWhite spot syndromeGene product
The invention provides a Cq-Ns1abp gene for inhibiting WSSV infection and application of protein thereof in resistance of virus activity and relates to white spot syndrome viruses. The Cq-Ns1abp geneis ligated into a prokaryotic expression vector pMal-C2x to construct an anti-WSSV infection regulatory factor pMal-C2x-Cq-Ns1abp recombinant expression vector of chrtax quadricarinatus. A Cq-Ns1abp gene product contains an N-end BTB structural domain and C-end Kelch structural domain protein and full-length protein; obtained recombinant expression vector transformants are introduced into host cells respectively for inducing expression to obtain expressed products, and rCq-Ns1abp recombinant protein with higher purity is obtained through affinity chromatography. Since Cq-Ns1abp has an inhibitory effect on WSSV infection, Cq-Ns1abp has an important effect on antiviral immunity of shrimps. Therefore, an anti-WSSV infection regulatory factor of chrtax quadricarinatus is applied in preparationof antiviral infection drugs and animal disease-resistant feed additives.
Owner:XIAMEN UNIV
Hemodialysis medical catheter for dialysis and preparation method of hemodialysis medical catheter
The invention relates to the technical field of medical catheters, in particular to a hemodialysis medical catheter for dialysis and a preparation method of the hemodialysis medical catheter. The medical catheter comprises a catheter body and an antibacterial coating coated on the surface of the catheter body, wherein the catheter body is prepared from polyvinyl chloride plastic, modified filter residues, magnesium carbonate, silicon dioxide and ethidene diamine; and the antibacterial coating is prepared from copper powder and an anti-infection drug. Mulberry bark is used as a raw material, is treated by a propyl alcohol solution, and cooperates with the magnesium carbonate, the silicon dioxide and the ethidene diamine, so that the antibacterial performance of the medical catheter is improved. The antibacterial coating is prepared from anti-infection medicine raw materials and sprayed to the surface of the medical catheter, and the antibacterial performance of the medical catheter can be further improved.
Owner:江苏松德生物科技有限公司
Cervinomycin B1, B2, B3 and B4 and production method and application thereof
The invention relates to cervinomycin B1, B2, B3 and B4 and a production method and application thereof. Chemical structures of the cervinomycin B1, B2, B3 and B4 are as shown in formulae of (1), (2),(3) and (4). The production method comprises the following steps: through fermenting and culturing streptomycete of which a preservation number is CGMCC NO. 16425, harvesting a fermentation culture object, and performing extracting, separating and purifying to obtain the cervinomycin B1-B4 components. The cervinomycin B1-B4 components are expected as a lead compound for researching and developingan anti-bacterial infection drug.
Owner:MEDICINE & BIOENG INST OF CHINESE ACAD OF MEDICAL SCI
Escherichia coli lyase as well as preparation method and application thereof
ActiveCN107502603AImprove the effect of prevention and controlEfficient penetrationAntibacterial agentsPeptide/protein ingredientsEscherichia coliSide effect
The invention relates to the field of biological engineering, in particular to an Escherichia coli lyase as well as a preparation method and application thereof as an anti-infection drug. The Escherichia coli lyase is characterized in that an amino acid sequence is Seq ID NO.2. Enzymic preparations capable of effectively killing Escherichia coli are developed by utilizing a bioengineering technology. The preparations can be used independently or can be compounded to use, can specifically deactivate multiple Escherichia coli, and a safe and nontoxic enzyme preparation source with no side effect can be provided for controlling the Escherichia coli in garget at present.
Owner:JIANGSU ACADEMY OF AGRICULTURAL SCIENCES
Application of antimicrobial peptides in anti-mycobacteria infection drugs
ActiveCN110615830AEnhanced inhibitory effectHigh antibacterial activityAntibacterial agentsPeptide/protein ingredientsAntimicrobial peptidesAntimycobacterial
The invention relates to the field of pharmacy, in particular to application of antimicrobial peptides in anti-mycobacteria infection drugs. According to the application, starting with antimicrobial peptides, a series of antimicrobial peptides aiming at mycobacteria with special structures and unusual action modes are researched and developed, the antimicrobial peptides kill bacteria through a membrane destruction mechanism, and the bacteria do not generate drug resistance. The antimicrobial peptides, as main potential medicament for treating tuberculosis, fill the gap of no new anti-tuberculosis drugs in China for a long time. Therefore, the antimicrobial peptides provided by the application can be used for preparing effective drugs aiming at the mycobacteria, are expected to be the anti-mycobacteria infection potential drugs, and are the main potential medicament for treating the tuberculosis.
Owner:LIAONING NORMAL UNIVERSITY
Application of benzydamine hydrochloride in preparation of medicine for treating or preventing influenza virus infection
ActiveCN103893171BImprove securityInhibition of replicationOrganic active ingredientsAntiviralsBenzydamine HydrochlorideViral infection
Owner:佛山熠然生物科技有限公司
Camptothecin E ring analogues and applications thereof as drugs
InactiveCN102603759AHigh activityGood metabolic stabilityOrganic active ingredientsOrganic chemistryDNA underwindingDiastereomer
The present invention relates to the technical field of medicine, particularly relates to camptothecin E ring analogues and applications of the camptothecin E ring analogues as drugs. The structures of the compounds provided by the invention are shown as general formula I, including forms of racemates, diastereoisomers and optional mixtures or pharmaceutically-acceptable salts of these forms. The compounds provided by the invention have function of inhibiting activity of topoisomerase I, and can be used for preparing antitumor drugs and antiviral or antifungal infection drugs.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Application of S-methylisothiourea sulfate in preparation of anti-influenza virus and escherichia coli co-infection drugs
InactiveCN112755012AInhibition of proliferation rateReduce loadAntibacterial agentsAntiviralsEscherichia coliVirus
The invention discloses application of S-methylisothiourea sulfate in preparation of anti-influenza virus and escherichia coli co-infection drugs. Experiments prove that at the cellular level, the compound S-methylisothiourea sulfate can significantly inhibit proliferation of escherichia coli under the condition of mixed infection; at the animal level, after S-methylisothiourea sulfate (20mg / kg / mouse) is dropped into a mouse in a nasal dropping mode, the resistance of the mouse to H9N2 subtype influenza virus and escherichia coli mixed infection is enhanced, the survival rate of the mouse infected with H9N2 subtype influenza virus and escherichia coli is increased compared with that of a mouse infected with H9N2 subtype influenza virus and escherichia coli without dropping S-methylisothiourea sulfate, and the carrying capacity of influenza virus and escherichia coli in the lung is obviously reduced. The compound is effectively applied to resisting influenza virus and escherichia coli mixed infection, can serve as a new candidate drug for resisting influenza virus and escherichia coli mixed infection, and provides more choices for treatment of influenza virus and escherichia coli mixed infection clinically.
Owner:FUJIAN AGRI & FORESTRY UNIV
Application of polycyclic aryl compound in preparation of antifungal drugs
ActiveCN113956215AHas a broad-spectrum antifungal effectLow toxicityOrganic active ingredientsAntimycoticsAntifungal drugPharmaceutical Substances
The invention provides a polycyclic aryl compound S1 for preparing antifungal infection drugs. The structural formula of the polycyclic compound is S1. The polycyclic aryl compound with the core-shell structure and shown in S1 is suitable for preparing drugs for resisting infection of pathogenic fungi such as candida, aspergillus and mucor, and has the following beneficial effects that the compound S1 has a broad-spectrum antifungal effect on the pathogenic fungi including but not limited to the candida, the aspergillus and the mucor, and is effective on azole drug-resistant candida, meanwhile, toxicity to mammals is low, systemic fungal infection can be treated through oral administration, and mucous film candida infection can be treated through local application.
Owner:THE FIRST AFFILIATED HOSPITAL OF JINAN UNIV
Antibacterial peptide liquid composition and preparation thereof
The invention provides an antibacterial peptide composition. The amino acid sequence of the antibacterial peptide is KWKSFLKTFaAbKTVLHTALKAISS, and substitution sites of a and b are selected from any amino acids as follows: L-leucine, D-leucine, L-valine, D-valine, L-alanine, D-alanine, glycine, L-serine, D-serine, L-lysine and D-lysine. The composition comprises at least one stabilizer, antibacterial peptide and a buffer system (preferably disodium hydrogen phosphate and citric acid), and the pH value of the composition is 3.5-5.5. The antibacterial peptide composition is a broad-spectrum anti-infection drug for local external use, is suitable for various primary skin infections caused by pathogenic bacteria, especially drug-resistant bacteria, and secondary skin infections such as eczema combined infection and ulcer combined infection, including stubborn infectious diseases such as diabetic foot, burn wound infection and bedsore infection, and has a wide application prospect.
Owner:JIANGSU PROTELIGHT PHARMA & BIOTECH
Application of adenosine or adenosine monophosphate in preparation of anti-infective drugs
PendingCN114159456AIncreased sensitivityDelay drug resistanceAntibacterial agentsOrganic active ingredientsMeropenemVibrio parahaemolyticus
The invention belongs to the technical field of biological medicine, and particularly relates to application of adenosine or adenosine monophosphate in preparation of anti-infective drugs. The invention relates to a preparation method of the medicine. Adenosine or adenosine monophosphate can significantly improve the effect of clinical escherichia coli, aeromonas hydrophila, vibrio including vibrio alginolyticus and vibrio parahaemolyticus, streptococcus pyogenes, pseudomonas aeruginosa, bacillus faecium, streptococcus iniae, acinetobacter baumannii, klebsiella pneumoniae and other bacteria on the effects of cefoperazone sulbactam, ceftazidime, ceftriaxone sodium, ceftazidime, ceftriaxone sodium, ceftazidime, ceftriaxone sodium, ceftazidime sodium and the like. The sensitivity of antibiotics such as cefoperazone, meropenem, imipenem, ciprofloxacin, ampenem, moxifloxacin, levofloxacin, gentamicin, amikacin, kanamycin and the like is improved, the compound can be used together with the antibiotics to serve as an anti-infection drug, bacteria are killed under the condition of low-concentration antibiotics, and a good anti-infection effect is achieved; meanwhile, the generation of bacterial drug resistance is reduced.
Owner:SUN YAT SEN UNIV
Determination method for anti-infective drugs in cosmetics
PendingCN114577950AExact derivationAccurate and fast derivationComponent separationCosmetic componentBiochemical engineering
The invention discloses a method for determining anti-infection drugs in cosmetics, and relates to the technical field of cosmetic component determination. The problems that the screening range is narrow and the detection method is inaccurate are solved. The method specifically comprises the following steps: preparing a determination material and a determination instrument, preparing a determination standard solution, preparing and determining three blank matrix solutions, determining instrument determination reference conditions including a chromatographic condition and a mass spectrum condition, carrying out parameter verification by adopting a QC sample, screening anti-infection drugs in cosmetics, calculating and establishing a database. The time-of-flight scanning mass spectrometry is adopted, so that the method has high selectivity, accuracy and precision, and has important practical significance for guaranteeing the quality safety of cosmetics and protecting the health of consumers.
Owner:ZHEJIANG INST FOR FOOD & DRUG CONTROL
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com